CEL-SCI Co. (NYSE:CVM - Get Free Report) shares traded up 10.9% during trading on Monday . The company traded as high as $10.99 and last traded at $10.56. 279,489 shares were traded during mid-day trading, a decline of 24% from the average session volume of 366,805 shares. The stock had previously closed at $9.52.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen assumed coverage on CEL-SCI in a research note on Friday, May 16th. They issued a "sell" rating on the stock.
Check Out Our Latest Analysis on CEL-SCI
CEL-SCI Stock Up 10.9%
The company has a market cap of $72.67 million, a price-to-earnings ratio of -22.00 and a beta of 0.52. The company has a current ratio of 1.07, a quick ratio of 1.09 and a debt-to-equity ratio of 0.66. The business has a fifty day moving average of $5.58 and a two-hundred day moving average of $6.74.
Insiders Place Their Bets
In other CEL-SCI news, CEO Geert R. Kersten purchased 29,197 shares of CEL-SCI stock in a transaction that occurred on Friday, July 25th. The stock was bought at an average price of $6.85 per share, with a total value of $199,999.45. Following the acquisition, the chief executive officer owned 72,835 shares of the company's stock, valued at $498,919.75. This trade represents a 66.91% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 9.93% of the company's stock.
Hedge Funds Weigh In On CEL-SCI
A hedge fund recently raised its stake in CEL-SCI stock. Bank of America Corp DE raised its position in shares of CEL-SCI Co. (NYSE:CVM - Free Report) by 2,188.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,981 shares of the company's stock after acquiring an additional 39,190 shares during the quarter. Bank of America Corp DE owned approximately 0.60% of CEL-SCI worth $94,000 as of its most recent SEC filing. 12.08% of the stock is currently owned by institutional investors and hedge funds.
About CEL-SCI
(
Get Free Report)
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CEL-SCI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CEL-SCI wasn't on the list.
While CEL-SCI currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access